Table 2.
Patient characteristics n(%)
|
Diagnosed Jan 2000-Dec 2004 |
Diagnosed Jan 2005-Dec 2008 |
|||||||||||||||
| MDT-Mix | MDT-No | MDT-Change | MDT-Yes | Other regions | MDT-Mix | MDT-No | MDT-Change | MDT-Yes | Other regions | |||||||
| Tumor type | ||||||||||||||||
| Oesophagus | 113 (15.4) | 31 (11.8) | 30 (14.6) | 68 (10.0) | 657 (12.9) | 91 (15.2) | 35 (16.2) | 30 (19.6) | 72 (12.8) | 571 (14.1) | ||||||
| Gastric | 258 (35.2) | 110 (41.8) | 77 (37.6) | 318 (47.0) | 2146 (42.2) | 214 (35.8) | 73 (33.8) | 45 (29.4) | 240 (42.6) | 1534 (38.0) | ||||||
| Pancreas | 362 (49.4) | 122 (46.4) | 98 (47.8) | 291 (43.0) | 2278 (44.8) | 293 (49.0) | 108 (50.0) | 78 (51.0) | 252 (44.7) | 1935 (47.9) | ||||||
| Total | 733 (100.0) | 263 (100.0) | 205 (100.0) | 677 (100.0) | 5081 (100.0) | 598 (100.0) | 216 (100.0) | 153 (100.0) | 564 (100.0) | 4040 (100.0) | ||||||
| Stage | ||||||||||||||||
| No metastasis | 109 (14.9) | 38 (14.4) | 28 (13.7) | 81 (12.0) | 694 (13.7) | 59 (9.9) | 30 (13.9) | 28 (18.3) | 71 (12.6) | 543 (13.4) | ||||||
| Lymph node metastasis | 155 (21.1) | 62 (23.6) | 49 (23.9) | 182 (26.9) | 1195 (23.5) | 125 (20.9) | 52 (24.1) | 44 (28.8) | 141 (25.0) | 926 (22.9) | ||||||
| Distant metastasis | 293 (40.0) | 104 (39.5) | 85 (41.5) | 303 (44.8) | 2083 (41.0) | 237 (39.6) | 97 (44.9) | 57 (37.3) | 237 (42.0) | 1642 (40.6) | ||||||
| Unknown | 176 (24.0) | 59 (22.4) | 43 (21.0) | 111 (16.4) | 1109 (21.8) | 177 (29.6) | 37 (17.1) | 24 (15.7) | 115 (20.4) | 929 (23.0) | ||||||
| Total | 733 (100.0) | 263 (100.0) | 205 (100.0) | 677 (100.0) | 5081 (100.0) | 598 (100.0) | 216 (100.0) | 153 (100.0) | 564 (100.0) | 4040 (100.0) | ||||||
MDT: Multidisciplinary team. No clinically relevant differences in stage distribution were revealed among the analyzed regions or between the two calendar periods. In addition, there were no clinically relevant differences in stage distribution among the studied counties.